Reduction of Hepatitis B Surface Antigen May Be More Significant in PEGylated Interferon-Alpha Therapy Combined with Nucleotide Analogues than Combined with Nucleoside Analogues in Chronic Hepatitis B Patients: A Propensity Score Matching Study
Table 3
Efficacy results at week 48 after PSM.
Responses
PegIFNα + NSs (n = 18)
PegIFNα + NTs (n = 36)
P (total)
P (ETV vs. ADV)
P (ETV vs. TDF)
P (ADV vs. TDF)
PegIFNα + ETV (n = 18)
PegIFNα + ADV (n = 18)
PegIFNα + TDF (n = 18)
HBsAg reduction from baseline at week 48, log10 IU/mL
–2.33
–3.52
0.032
–2.33
–3.55
–3.49
0.092
0.035
0.039
0.853
HBeAg reduction from baseline at week 48, s/co
–394.33
–478.72
0.667
–394.33
–618.26
–356.63
0.417
0.301
0.862
0.236
HBV DNA reduction from baseline at week 48, log10 IU/mL
–3.32
–4.72
0.194
–3.32
–4.85
–4.60
0.426
0.240
0.311
0.840
HBsAg loss, n (%)
4 (22.2)
3 (8.3)
0.205
4 (22.2)
1 (5.6)
2 (11.1)
0.316
0.338
0.658
1.000
HBeAg loss, n (%)
3 (23.1)
4 (13.8)
0.657
3 (23.1)
2 (14.3)
2 (13.3)
0.764
0.648
0.639
1.000
HBeAg seroconversion, n (%)
2 (15.4)
3 (10.3)
0.637
2 (15.4)
1 (7.1)
2 (13.3)
0.773
0.596
1.000
1.000
HBV DNA undetectable, n (%)
17 (94.4)
33 (94.3)
1.000
17 (94.4)
15 (88.2)
18 (100.0)
0.221
0.603
1.000
0.229
HBsAg reduction >1 log10 from baseline, n (%)
13 (72.2)
36 (100.0)
0.003
13 (72.2)
18 (100.0)
18 (100.0)
0.002
0.045
0.045
—
HBsAg reduction >1 log10 and DNA undetectable, n (%)
